12:00 AM
 | 
Dec 15, 2008
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 12/12 cls
Arena (NASDAQ:ARNA) Fortis Patrick Moriarty Price target Buy 6% $3.83
UBS Jeff Elliott Price target Buy
Moriarty lowered his target to $17 from $22 after Arena's APD125 missed the primary endpoint in a Phase IIb trial to treat insomnia. The company said it will complete an analysis of the data but does not expect to further develop the inverse agonist of serotonin (5-HT2A) receptor (see B13).
Elliott lowered his target to $6 from $8 on the APD125 news.
Biodel (NASDAQ:BIOD) Ladenburg Thalmann Matthew Kaplan Price target Buy -7% $2.29
Kaplan lowered his target to $9.50 from $11...

Read the full 847 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >